Please assess the completion status of the following clinical trial:

Trial Title: Lovaza's Effect on the Activation of Platelets

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females older than 18 years old who are able to ingest omega n3 fatty acids are eligible for this trial and are:~* On no antiplatelet and anticoagulation therapy, OR~* On chronic therapy with warfarin or aspirin alone (\< or =325 mg/day)or combination therapy with clopidogrel and aspirin (\< or =325 mg/day).~* The subject must be able to read, understand, and sign an informed consent form and follow protocol.~* To be enrolled in the study, subjects must be clinically stable on stable medical therapy throughout the duration of the study and meet the following criteria:~* Healthy volunteers~* Volunteers with stable coronary artery disease are those with:~* Prior MI (\>1 month) OR~* Prior revascularization: angioplasty ± stenting (\> 1 month) OR~* Coronary artery bypass grafting (\>3 months) OR~* Documented disease on coronary angiography.~* No planned no planned procedures or changes in medical therapies over the 24-week duration of the study~* Volunteers with stable atrial fibrillation are those with:~* Rate-controlled or paroxysmal atrial fibrillation on stable antiarrhythmic therapy.~* On a stable dose of warfarin and regular follow-up in an anticoagulation (coumadin) clinic.~* No planned changes in antiarrhythmic therapies or cardioversion during the duration of the study.~* No recent admissions for atrial fibrillation (\> 3 months)~* Subjects may not ingest other drugs known to cause a significant platelet abnormality while participating in this trial. (See list of prohibited medications, as outlined in Section 9)~* Patients must be assessable to the investigator for scheduled clinic visits during the duration of the trial.~* All female subjects of child bearing potential must have a negative serum pregnancy test prior to randomization and not plan on getting pregnant for the duration of the study.~Exclusion Criteria:~* Any medical condition that would preclude ingestion of omega n3 fatty acids (Lovaza®).~* Subjects taking nutritional supplements of fish oil or flaxseed oil. These patients may become eligible if they are willing to discontinue these nutritional supplements for a 2-week washout period.~* Any other medical condition that would adversely affect the study objectives.~* Chronic medical conditions known to be associated with abnormal platelet function including:~* Liver dysfunction including abnormal liver function tests (AST, ALT, or alkaline phosphatase \> upper limit of normal), known cirrhosis or chronic hepatitis.~* Chronic kidney disease with a calculated creatinine clearance \< 60 ml/min (MDRD) and/or a serum creatinine \> 2.0 mg/dl.~* History of significant anemia, or baseline hemoglobin \< 11.0 g/dl.~* Baseline PT\>ULN, INR\>1.3, and aPTT\>ULN in subjects who are not on chronic warfarin therapy.~* History of thrombocytopenia, or baseline platelet count of \< 100,000~* History of thrombocytosis, or baseline platelet count of \> 600,000~* Known bleeding diathesis and/or congenital hemostasis disorder and/or congenital platelet abnormalities.~* Any history of stroke in the past 12 months.~* History of peptic ulcer disease in the past year or gastrointestinal bleeding in the last 3 months.~* Genitourinary bleeding in the last 3 months.~* HIV or other infectious diseases that would expose laboratory personnel to unacceptable risks.~* Treatment within 30 days with an antiplatelet agent other than aspirin or clopidogrel such as eptifibatide, tirofiban or abciximab.~* Treatment within the past 7 days with unfractionated or low-molecular- weight heparin.~* Allergy to iodine, fish, or other components of the study drug.~* Alcohol or substance abuse.~* Emotionally or psychiatrically unstable.~* Use of any investigational drug or device within the past 30 days~* Any other factor that the investigator feels would put the patient at increased risk if participating in the study.~* Any Terminal illness or illness that may cause mortality that could obscure the results of the test in any way for them to appear inaccurate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
- B (Type: ACTIVE_COMPARATOR): Patient is on regular dose of Aspirin ( \< or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
- C (Type: ACTIVE_COMPARATOR): Patient is taking regularly 75mg of clopidogrel daily and Aspirin (\< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
- D (Type: ACTIVE_COMPARATOR): Patient is regularly taking Warfarin daily and Aspirin (\< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete